Study of a heart drug for first-time heart attack patients
Part of Heart & circulation clinical trials.
This trial tests a new drug given shortly after a first heart attack to see if it can reduce heart damage when blood flow is restored. It is for patients having a specific type of heart attack (STEMI) and getting a procedure to open the blocked artery within 6 hours of symptoms starting.
Summary written for real people, not researchers, by Clin2.
Who can take part
- You are having your first heart attack (a type called STEMI that shows on an EKG).
- You are scheduled for a procedure to open the blocked artery (angioplasty or PCI) within 6 hours of symptoms starting, and doctors expect to start the procedure in less than 2 hours after you arrive at the hospital.
- You are a man between 40 and 75 years old, or a woman between 55 and 75, or a woman 40–55 who cannot become pregnant.
- Your blood pressure, heart rate, and oxygen levels must be stable, and you must be in Killip class I or II (meaning your heart failure symptoms are mild or none).
- You must not have had a heart attack or major heart surgery before, and you cannot have certain conditions that would make an MRI or the study drug unsafe (like kidney problems, pacemaker, or allergy to soy or egg).
- If you are a man with a partner who could become pregnant, you must agree to use effective birth control for at least 7 days after receiving the study drug.
Quick eligibility check
Answer a few plain-language questions, based on this study's own requirements, to get a preliminary sense of fit.
Similar studies
Other trials that look related to this one.
This trial tests whether a medication called ranolazine can help prevent damage to tiny blood vessels in the heart after a certain type of heart attack (STEMI). You may be eligible if you recently had this kind of heart attack and had a successful procedure to open a blocked artery, but still have other blockages that can be treated with stents.
This study uses special heart and blood vessel imaging to see how two new medicines affect inflammation and healing after a heart attack. It is an early-stage trial that may help doctors improve recovery after a heart attack.
This trial tests a new way to treat heart attacks by using a special balloon to deliver medication to the heart's small blood vessels during a standard stenting procedure. It may help reduce damage to the heart muscle after a heart attack.
This trial compares two ways to guide treatment during a heart attack: using a special camera (OCT) inside the artery or standard X-ray (angiography). It aims to see which method leads to better results for patients.
This trial tests whether a low-dose clot-busting medicine placed into the heart artery after a primary stent can improve outcomes in people with a certain type of heart attack. It also involves short hospital follow-ups and a heart MRI to look at how the heart is recovering.
This trial tests a heart medication (a cardio-selective beta-blocker) given during a heart attack to see if it reduces damage to the heart muscle. It might help people having their first heart attack who are treated quickly with angioplasty (a procedure to open blocked arteries).
Hear when a new Reperfusion Injury trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.